3. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGMA. Bronchodilator effect of inhaled formoterol vs. salbutamol over 12 hours. Chest 1990; 97: 590-594.
4. Chapman KR„ Kesten S, Szalai JP. Regular vs. as-needed inhaled salbutamol in asthma control. Lancet 1994; 343:1379-1382.
5. Drazen JM, Israel E, Boushey HA, el al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. New Engl J Med 1996; 335: 841-847.
6. Arvidsson P, Larsson S, Lofdahl C-G. el al. Formoter-ol, a new long-acling bronchodilalor for inhalation. Ew Resp J 1989; 2:325-330.
7. Wallin A, Mclander В, Rosenhall L, el at. Formoterol, a new long acting b2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259-261.
8. Arvidsson P, Larsson S, Lofdahl C-G, et at. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Ew Resp J 1991; 4; 1168-1173.
9. Midgren В, Milandcr В, Persson G. Fonnotcrol. a new long-acting b2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992; 1Ф1: 1019-1022.
10. Kestcn S, Chapman KR, Brodcr I, el al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albutamol in the management of stable asthma. Am Rev Respir Dis 1991; 144; 622-625.
11. Steffensen I, Faurschou P, Riska H, el al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995; 50: 657-663
12. FitzGerald JM, Chapman K.R, Delia Cioppa G, el al. and The Canadian FO/OD1 Study Group. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immuwl 1999; ИЗ: 427-435.
13. American Thoracic Society. (American Lung Association). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Resp Dis 1987; 136: 225-244.
14. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Mod 1991; 85(Suppl B): 25-31.
15. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmetcrol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
16. Busse WW. Long- and short-acting b2-adrenergic agonists. Effects on airway function in patients with asthma. Arch Intern Mod 1996:156 1514-1520.
17. Crane J, Pcarcc N, Burgess C, Beasley R. Asthma and the b2-agonist debate. Thorax 1995; S^Suppl.l): S5-S10.
18. Pauwels RA, Lofdahl C-G, Postma DS, et al. On behalf of the FACET International Study Group. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations: a 1-year, controlled" study. N EngI J Med 1997; 337: 1405-1411.
19. Tattersfield AE, Postma DS, Bames PJ, et al. On behalf of the FACET International Study Group. Exacerbations of asthma, a descriptive study of 425 severe exacerbations. Am J Respir Crii Care Med 1999; 160:594-599.
20. Molimard M, Naline E, Zhang Y, el al. Long- and short-acting b2-adrenoceptor agonists interactions in human contracted bronchi. Eur Resp J 1998; 11: 583-588.
21. Vervloet D, Ekstrom Т, Pela R. et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease.
Respir Med 1998; 92:836-842.
22. Clauzel A-M, Molimard M, Le Gros V, et al.Use of formoterol dry powder administered for three months via a single-dose inhaler in 1380 asthmatic patients. Invest Allergol Clin Immunol 1998; 8: 265-270.
23. Jones PW, Brambilla R, Till MD. Quality of life in patients treated with two long-acting b2-agonists: Formoterol and salmeterol [Abstract]. Eur Resp J 1997; 10 (Suppl.25): 3S.
Уважаемый посетитель!
Чтобы распечатать файл, скачайте его (в формате Word).
Ссылка на скачивание - внизу страницы.